Board member Ramiro Guerrero, JD, LL.M. has increased his ownership stake in the Company through ope

CHICAGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”,

PIMCO economist Tiffany Wilding said labor markets are no longer a major source of inflation pressur

Next-generation divalent agents show increased anticancer activity in preclinical in vitro and in vi

Gainers Intelligent Bio Solutions (NASDAQ:INBS) stock moved upwards by 8.2% to $2.63 during Tuesday

New York, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm

MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.13) per share which missed the analy

Anna Edwards, Guy Johnson and Adam Linton break down today's key themes for analysts and investors o

90.5% interim disease control rate (DCR) observed with combination therapyInitial Part C efficacy ob

90. 5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy

MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph

Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (G

Georgia's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recogniz

Additional data from MAIA's THIO-101 expansion may further support an accelerated approval filing wi

MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph

MAIA's novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-s

Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Ap

Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Ap

Approximately 72,700 shares of MAIA common stock were purchased by Dr. Vitoc on June 6, 2026, at an

CHICAGO, June 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", t

THIO-104 evaluates the efficacy of MAIA's telomere targeting agent, ateganosine, administered in

CHICAGO, June 01, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, t

New York, May 18, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm w

MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.14) per share which beat the analyst

MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph

Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control,

Potential breakthrough therapeutic targets $50B+ global immunotherapy market1CHICAGO, March 31, 2026

MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.08) per share which beat the analyst

US stocks down amid Iran-US conflict. Tehran closed Strait of Hormuz & warned of firing on vesse

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 900 points on Tues

Shares of Ouster Inc (NASDAQ:OUST) rose sharply in pre-market trading after the company reported bet

MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biop

Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical succ

MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph

MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biop

Key milestone achieved as Company advances clinical program to full approval trial of ateganosine se

MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph

Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countr

Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO

MAIA's Board of Directors authorizes holdings of up to 90% of the Company's liquid assets in

THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third

MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph

Poster details durability and efficacy of ateganosine (THIO) treatment in non-small cell lung cancer